In a significant move to reshape the landscape of medical diagnostics and disease prevention in Nigeria, Pharmaplus Nigeria Ltd has officially announced plans to forge a strategic partnership with NURA Preventive Healthcare Screening, a premier health-tech organization based in Gurugram, New Delhi, India. This collaboration seeks to introduce advanced, AI-driven diagnostic capabilities to the Nigerian market, aiming to shift the national healthcare paradigm from reactive treatment to proactive early detection.
The announcement follows a high-level site visit to the NURA facility in India by the Founder and Chief Executive Officer of Pharmaplus Nigeria Ltd, Pharm. Ahmed I. Yakasai. During this visit, Mr. Yakasai engaged with NURA’s leadership, including Dr. Abhay Kumar, Head of Business for NURA India, to discuss the technical requirements, logistical frameworks, and clinical benefits of transplanting the NURA screening model into the Nigerian healthcare ecosystem.
The Evolution of Preventive Healthcare
Preventive healthcare is increasingly recognized by global health organizations as the most sustainable strategy for reducing the burden of non-communicable diseases (NCDs). According to the World Health Organization (WHO), NCDs, such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are the leading cause of mortality worldwide. In Nigeria, the rising prevalence of these conditions is exacerbated by a lack of early-detection infrastructure, often resulting in patients presenting for care only when diseases have reached advanced, and frequently untreatable, stages.
The NURA model serves as a direct response to this challenge. Developed as a joint venture between Fujifilm—a global titan in medical imaging technology—and Dr. Kutty’s Healthcare, the institution leverages cutting-edge artificial intelligence to perform comprehensive screenings in a fraction of the time required by traditional diagnostic centers.
Technological Integration and Clinical Precision
At the heart of the proposed collaboration is the integration of NURA’s proprietary screening technology. The system is designed to assess over 18 different organs within a single session, utilizing ultra-low-dose Computed Tomography (CT) scans combined with advanced blood biomarkers. This dual-pronged approach allows for the early identification of major health risks, including various forms of cancer: oral, lung, liver, kidney, pancreatic, colon, prostate, breast, cervical, and ovarian.
The reliance on AI-powered analytics ensures a high level of precision, minimizing the margin of human error that can occur in conventional diagnostic radiology. For the Nigerian context, this represents a quantum leap in healthcare service delivery. Pharmaplus, which already manages specialized divisions such as IntraHub Technologies for pharmacovigilance and RxBook, an AI-powered digital medicines formulary, views this partnership as the missing piece in its integrated healthcare strategy.
Chronology of the Strategic Engagement
The partnership follows a period of deliberate scouting for international technical partners by the management of Pharmaplus. The timeline for this collaboration can be traced back to early 2026, as Pharmaplus sought to expand its digital healthcare footprint.
- Strategic Planning (Q1-Q2 2026): Pharmaplus identifies the need for high-end diagnostic infrastructure to complement its existing pharmaceutical and digital medicine portfolio.
- Initial Outreach (Q2 2026): Engagement begins with NURA India to assess the feasibility of cross-border technology transfer.
- The Executive Visit (September 2026): Pharm. Ahmed I. Yakasai visits the Gurugram facility to witness the operational workflow, meet the technical team, and evaluate the efficacy of the Fujifilm-backed imaging systems.
- Formal Announcement (September 14, 2026): Following the successful evaluation, the intent to partner is made public, marking the commencement of the regulatory and operational planning phase.
Official Perspectives and Institutional Alignment
Pharm. Ahmed I. Yakasai, a former President of the Pharmaceutical Society of Nigeria (PSN), emphasized that the visit to the Indian facility was not merely an observational tour but a strategic alignment of vision. "I was particularly excited by the possibilities this presents for Africa and, especially, Nigeria," Yakasai noted. He underscored that the professionalism and clinical hospitality experienced at the Gurugram site serve as a benchmark for the standards he intends to implement locally.
By bringing the NURA model to Nigeria, Pharmaplus aims to bridge the gap in diagnostic accessibility. While the logistical details—such as the location of the first screening center and the timeline for equipment deployment—are currently being finalized, the objective remains clear: to provide a centralized, efficient, and technology-backed screening service that demystifies early diagnosis for the average citizen.
Impact and Economic Implications
The introduction of such advanced screening technology is expected to have a multi-fold impact on the Nigerian healthcare sector:
- Reduced Mortality Rates: By facilitating early diagnosis of life-threatening diseases, the collaboration is projected to significantly improve survival rates for conditions that are currently detected too late in the Nigerian healthcare system.
- Economic Efficiency: While the initial cost of high-tech screenings can be high, the long-term economic burden of treating late-stage cancers and chronic lifestyle diseases is significantly higher. Preventive screening is a cost-effective intervention that reduces the long-term financial strain on the health system and households.
- Technology Transfer: The collaboration serves as a conduit for the transfer of advanced Japanese and Indian medical technology to the Nigerian workforce, fostering capacity building among local healthcare professionals.
- Data-Driven Healthcare: The use of AI-powered analytics will generate critical health data that can help the Nigerian government and healthcare providers better understand the prevalence of specific diseases, allowing for more targeted public health interventions.
Addressing the Challenges of Implementation
Despite the promise of the partnership, experts point to the need for robust supporting infrastructure. Implementing ultra-low-dose CT technology requires consistent power supply, specialized maintenance teams, and a regulatory framework that ensures data privacy and quality control. Pharmaplus, with its established presence in the Nigerian health-tech sector via IntraHub Technologies, is well-positioned to navigate these operational challenges.
The partnership with NURA also aligns with the global trend of "Medical Tourism in Reverse." Instead of relying solely on international travel for high-quality diagnostic imaging, bringing world-class screening technology into the country allows for local capacity building, keeping patients within the domestic healthcare network.
Conclusion: A Vision for the Future
The proposed collaboration between Pharmaplus Nigeria Ltd and NURA Healthcare represents a pivotal moment in the modernization of the Nigerian health sector. By combining the local market intelligence of an established pharmaceutical entity like Pharmaplus with the technological prowess of an international leader in preventive screening, there is a clear path toward a more resilient and proactive health infrastructure.
As the parties move from the memorandum of understanding phase to implementation, the focus will likely shift to training local clinicians and ensuring that the NURA diagnostic model is accessible to a broad demographic. If successful, this initiative could serve as a blueprint for future public-private partnerships in the Nigerian medical sector, proving that with the right technology and strategic vision, the trajectory of preventable disease can be fundamentally altered.
